TABLE 3.
| Study Characteristics/Findings | INSTRIDE 2 Trial | ELEMENT 2 Trial |
|---|---|---|
| Population | Type 2 diabetes (n = 560) | Type 2 diabetes (n = 756) |
| Study length, weeks | 24 | 24 |
| Treatment | Semglee | Abasaglar |
| Mean change in A1C from baseline to week 24, % | −0.60 with Semglee versus −0.66 with reference insulin glargine | −1.29 with Abasaglar versus −1.34% with reference insulin glargine |
| Hypoglycemia rate (total), % | 22.5 versus 19.9 | 21.3 versus 22.3 |
| Immunogenicity, % | 25.4 versus 27.0 | 15 versus 11 |